349 related articles for article (PubMed ID: 31507061)
1. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.
Manchanda R; Burnell M; Gaba F; Desai R; Wardle J; Gessler S; Side L; Sanderson S; Loggenberg K; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Legood R; Beller U; Tomlinson I; Menon U; Jacobs I
BJOG; 2020 Feb; 127(3):364-375. PubMed ID: 31507061
[TBL] [Abstract][Full Text] [Related]
2. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term secondary lifestyle behavioural outcomes.
Burnell M; Gaba F; Sobocan M; Desai R; Sanderson S; Loggenberg K; Gessler S; Side L; Brady AF; Dorkins H; Wallis Y; Jacobs C; Legood R; Beller U; Tomlinson I; Wardle J; Menon U; Jacobs I; Manchanda R
BJOG; 2022 Nov; 129(12):1970-1980. PubMed ID: 35781768
[TBL] [Abstract][Full Text] [Related]
3. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
Manchanda R; Burnell M; Gaba F; Sanderson S; Loggenberg K; Gessler S; Wardle J; Side L; Desai R; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
BJOG; 2019 May; 126(6):784-794. PubMed ID: 30767407
[TBL] [Abstract][Full Text] [Related]
4. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Manchanda R; Loggenberg K; Sanderson S; Burnell M; Wardle J; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; McGuire A; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):379. PubMed ID: 25435541
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract][Full Text] [Related]
9. Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral.
Lieberman S; Tomer A; Ben-Chetrit A; Olsha O; Strano S; Beeri R; Koka S; Fridman H; Djemal K; Glick I; Zalut T; Segev S; Sklair M; Kaufman B; Lahad A; Raz A; Levy-Lahad E
Genet Med; 2017 Jul; 19(7):754-762. PubMed ID: 27929526
[TBL] [Abstract][Full Text] [Related]
10. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
[TBL] [Abstract][Full Text] [Related]
12. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
Tennen RI; Laskey SB; Koelsch BL; McIntyre MH; Tung JY
Sci Rep; 2020 May; 10(1):7669. PubMed ID: 32376921
[TBL] [Abstract][Full Text] [Related]
13. Population-based screening of Uruguayan Ashkenazi Jews for recurrent BRCA1 and BRCA2 pathogenic sequence variants.
Castillo C; Artagaveytia N; Brignoni L; Laitman Y; Camejo N; Hernández AL; Krygier G; Cayota A; Delgado L; Friedman E
Mol Genet Genomic Med; 2022 Jun; 10(6):e1928. PubMed ID: 35332707
[TBL] [Abstract][Full Text] [Related]
14. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
[TBL] [Abstract][Full Text] [Related]
15. Current detection rates and time-to-detection of all identifiable
Manchanda R; Blyuss O; Gaba F; Gordeev VS; Jacobs C; Burnell M; Gan C; Taylor R; Turnbull C; Legood R; Zaikin A; Antoniou AC; Menon U; Jacobs I
J Med Genet; 2018 Aug; 55(8):538-545. PubMed ID: 29622727
[TBL] [Abstract][Full Text] [Related]
16. Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study.
Reisel D; Burnell M; Side L; Loggenberg K; Gessler S; Desai R; Sanderson S; Brady AF; Dorkins H; Wallis Y; Jacobs C; Legood R; Beller U; Tomlinson I; Wardle J; Menon U; Jacobs I; Manchanda R
BJOG; 2022 May; 129(6):959-968. PubMed ID: 34758513
[TBL] [Abstract][Full Text] [Related]
17. Clinicians' attitudes toward general screening of the Ashkenazi-Jewish population for prevalent founder BRCA1/2 and LRRK2 mutations.
Shkedi-Rafid S; Ofer-Bialer G; Meiner V; Calderon-Margalit R
Public Health Genomics; 2013; 16(4):174-83. PubMed ID: 23816973
[TBL] [Abstract][Full Text] [Related]
18. What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?
Bosch N; Junyent N; Gadea N; Brunet J; Ramon y Cajal T; Torres A; Graña B; Velasco A; Darder E; Mensa I; Balmaña J
Breast; 2012 Dec; 21(6):755-60. PubMed ID: 22381151
[TBL] [Abstract][Full Text] [Related]
19. BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.
Shkedi-Rafid S; Gabai-Kapara E; Grinshpun-Cohen J; Levy-Lahad E
Genet Med; 2012 Jul; 14(7):688-94. PubMed ID: 22481128
[TBL] [Abstract][Full Text] [Related]
20. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
